Non-invasive prostate MiRNA Scientific offers a non-invasive urine liquid biopsy test for prostate cancer, suggesting a sales angle to urology clinics, oncology practices, and primary care networks seeking less invasive diagnostics for cancer management.

Value-based care The company emphasizes a precision healthcare platform aimed at value-based cancer care, presenting opportunities to partner with healthcare providers, payer organizations, and hospital systems pursuing outcomes-based reimbursement models.

Early engagement With a focused initial test in prostate cancer and a scalable cloud-based platform, target-building outreach to urology and oncology departments, lab networks, and regional cancer centers could accelerate adoption and expand test utilization.

Growth readiness Revenue in the mid tens of millions and a lean employee base indicate a scalable solution; opportunities exist to upsell integration, lab processing partnerships, and expanded test panels as the platform matures.

Tech & trust Leverage the cloud-native tech stack and modern web delivery to pitch a robust, secure partner ecosystem; emphasize data security, interoperability, and compliant workflows to win contracts with hospitals and research labs.